tbuckley/cabot-search huggingface dataset:
The longitudinal impact of probiotic and peanut oral immunotherapy on health‐related quality of life
Authors: A. Dunn Galvin, S. McMahon, A.‐L. Ponsonby, K.‐C. Hsiao, M. L. K. Tang
Journal: Allergy (2017)

Abstract Background We previously reported that probiotic and peanut oral immunotherapy (PPOIT) was effective at inducing sustained unresponsiveness compared with placebo in a double‐blind, placebo‐controlled randomized trial. This study evaluated the impact of PPOIT on health‐related quality of life (HRQL). Method Fifty‐one participants (PPOIT 24; placebo 27) from the PPOIT trial completed Food Allergy Quality of Life Questionnaire (FAQLQ‐PF) and Food Allergy Independent Measure (FAIM) at pre‐treatment, end‐of‐treatment and 3 months after end‐of‐treatment. A total of 42 participants (20 PPOIT; 22 placebo) completed measures at 12 months post‐treatment. Changes over time in PPOIT and placebo groups were examined by repeated‐measures analysis of variance and paired t tests. Results Probiotic and peanut oral immunotherapy was associated with significant improvement in FAQLQ‐PF ( F = 3.63, P = .02), with mean difference 0.8 at 3 months post‐treatment ( P = .05) and 1.3 at 12 months post‐treatment ( P = .005), exceeding the 0.5 minimal clinically important difference for FAQLQ‐PF. For FAIM, mean difference was 0.5 ( P = .03) at 3 months and 0.4 ( P = .04) at 12 months post‐treatment. In placebo group, post‐treatment FAQLQ and FAIM remained unchanged from pretreatment. Improvement in FAQLQ‐PF and FAIM scores related specifically to acquisition of sustained unresponsiveness rather than to receiving PPOIT treatment or participation in the trial. Conclusions Probiotic and peanut oral immunotherapy has a sustained beneficial effect on psychosocial impact of food allergy at 3 and 12 months after end‐of‐treatment. Treatment was not associated with reduced HRQL relative to baseline in either PPOIT or placebo groups, indicating that PPOIT was well tolerated and psychological well‐being was not negatively impacted. Improved HRQL was specifically associated with acquisition of sustained unresponsiveness.
Increased Cardiac Arrhythmogenesis Associated With Gap Junction Remodeling With Upregulation of RNA-Binding Protein FXR1
Authors: Miensheng Chu, Stefanie Mares Novak, Cathleen Cover, Anne A. Wang, Ikeotunye Royal Chinyere, Elizabeth B. Juneman, Daniela C. Zarnescu, Pak Kin Wong, Carol C. Gregorio
Journal: Circulation (2017)

Background: Gap junction remodeling is well established as a consistent feature of human heart disease involving spontaneous ventricular arrhythmia. The mechanisms responsible for gap junction remodeling that include alterations in the distribution of, and protein expression within, gap junctions are still debated. Studies reveal that multiple transcriptional and posttranscriptional regulatory pathways are triggered in response to cardiac disease, such as those involving RNA-binding proteins. The expression levels of FXR1 (fragile X mental retardation autosomal homolog 1), an RNA-binding protein, are critical to maintain proper cardiac muscle function; however, the connection between FXR1 and disease is not clear. Methods: To identify the mechanisms regulating gap junction remodeling in cardiac disease, we sought to identify the functional properties of FXR1 expression, direct targets of FXR1 in human left ventricle dilated cardiomyopathy (DCM) biopsy samples and mouse models of DCM through BioID proximity assay and RNA immunoprecipitation, how FXR1 regulates its targets through RNA stability and luciferase assays, and functional consequences of altering the levels of this important RNA-binding protein through the analysis of cardiac-specific FXR1 knockout mice and mice injected with 3xMyc-FXR1 adeno-associated virus. Results: FXR1 expression is significantly increased in tissue samples from human and mouse models of DCM via Western blot analysis. FXR1 associates with intercalated discs, and integral gap junction proteins Cx43 (connexin 43), Cx45 (connexin 45), and ZO-1 (zonula occludens-1) were identified as novel mRNA targets of FXR1 by using a BioID proximity assay and RNA immunoprecipitation. Our findings show that FXR1 is a multifunctional protein involved in translational regulation and stabilization of its mRNA targets in heart muscle. In addition, introduction of 3xMyc-FXR1 via adeno-associated virus into mice leads to the redistribution of gap junctions and promotes ventricular tachycardia, showing the functional significance of FXR1 upregulation observed in DCM. Conclusions: In DCM, increased FXR1 expression appears to play an important role in disease progression by regulating gap junction remodeling. Together this study provides a novel function of FXR1, namely, that it directly regulates major gap junction components, contributing to proper cell-cell communication in the heart.
Introduction to the 2017 Cardiovascular Surgery–Themed Issue of <i>Circulation</i>
Authors: Marc Ruel, Timothy J. Gardner
Journal: Circulation (2017)

he past year in cardiac surgery has been particularly fertile from an academic point of view, with the results of 2 large clinical trials (NOBLE [Nordic-Baltic-British Left Main Revascularisation Study] and EXCEL [Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization]) providing additional information about percutaneous coronary intervention versus bypass surgery for the treatment of left main coronary artery stenosis; 1 clinical trial showed better outcomes with a new left ventricular assist device; and the 5-year results of the ART trial (Arterial Revascularisation Trial) failed to show a difference in outcomes between patients having single versus double internal thoracic artery use at bypass surgery.Meanwhile, cardiac surgery continues to evolve at both ends of the procedural spectrum, from increasingly complex valve repair, aortic and congenital operations, to more streamlined and routine hybrid treatment platforms, where interventional cardiology, vascular surgery, and cardiac surgery become a single therapeutic entity.In this 2017 Cardiovascular Surgery-Themed Issue of Circulation, our editorial team has gathered a fine selection of original research, state-of-the-art, and perspective articles on congenital, coronary, peripheral vascular, and heart failure surgery, which will appeal not only to cardiovascular surgeons, but also to the vast readership of Circulation.The reader will find each article to be of relevance to the community and academic cardiovascular practitioner, with topics such as adult congenital heart conditions, new controversies in coronary surgery, the stillprevalent problem of ventricular assist device malfunction, and a population-based landscape of abdominal aortic aneurysm treatment.We anticipate that this Surgery Themed Issue will again appeal to a wide readership because it gathers some of the year's best contributions to the cardiovascular field around surgical conditions and treatment, with potential impact on millions of patients worldwide.
Case 33-2017
Authors: Brian M. Cummings, Michael S. Gee, Oscar J. Benavidez, Erik S. Shank, Branko Bojovic, Kevin A. Raskin, Allan M. Goldstein
Journal: New England Journal of Medicine (2017)

Dicephalic, dithoracic, omphalo-ischiopagus 22-month-old conjoined twins were evaluated in the pediatric surgery clinic. Twin A was smaller and less active than Twin B; imaging studies revealed complex congenital heart disease. Management decisions were made.
Legionelosis asociada a los viajes en Europa en 1999
Authors: C Joseph
Journal: Eurosurveillance (2001)

En 1999, el Sistema Europeo de Vigilancia de la legionelosis asociada a viajes (European Surveillance Scheme for Travel Associated Legionnaires’ Disease) recibio notificacion del mayor numero de casos desde que el sistema comenzo en 1987. Ello refleja una mejora en las actividades de vigilancia y un aumento en el uso de la deteccion del antigeno urinario para Legionella pneumophila del serogrupo 1. En algunos paises, las amplias actividades de notificacion e investigacion, realizadas en el marco del programa, son complementadas por las llevadas a cabo por las agencias de turismo que, desde la promulgacion en 1996 por la Comision Europea de la Directriz en materia de Paquetes Turisticos, tienen responsabilidad juridica sobre la salud y la seguridad de sus clientes. En los ultimos anos, la labor coordinada de nuestros colaboradores ha contribuido a fortalecer la vigilancia y el control en los lugares mas frecuentados por los viajeros.
Carne de vaca picada e salmonelose humana: revisão da investigação de três surtos ocorridos em França
Authors: S Haeghebaert, L Duché, C Gilles, B Masini, M Dubreuil, J C Minet, P Bouvet, F Grimont, E Delarocque Astagneau, V Vaillant
Journal: Eurosurveillance (2001)

A sintese das investigacoes de tres surtos de salmonelose que ocorreram em Franca, entre 1998 e 2000, confirma o papel do consumo de carne de vaca picada e realca a importância das medidas de prevencao.
Strengthening the ACA for the Long Term
Authors: Linda J. Blumberg, John Holahan
Journal: New England Journal of Medicine (2017)

Interview with Dr. Linda Blumberg on proposals for stabilizing insurance markets and making nongroup insurance more affordable. (12:29)Download The problems with the nongroup insurance market, though significant, are fixable, and correcting them does not necessitate disruption of coverage for the 94% of the population that gets its coverage from other sources. Some key policies could stabilize the markets quickly.
TCT-517 Changes in Aortomitral Annular Angle After Transcatheter Aortic Valve Replacement: Implications for Transcatheter Mitral Valve Replacement?
Authors: Gilbert Tang, Mohammad Khan, Syed Zaid, Tanya Dutta, Mala Sharma, Angelica Poniros, Hasan Ahmad, Ryan Kaple, Martin Cohen, Steven Lansman
Journal: Journal of the American College of Cardiology (2017)
Stem cells and heart disease - Brake or accelerator?
Authors: Gustav Steinhoff, Julia Nesteruk, Markus Wolfien, Jana Große, Ulrike Ruch, Praveen Vasudevan, Paula Müller
Journal: Advanced Drug Delivery Reviews (2017)

After two decades of intensive research and attempts of clinical translation, stem cell based therapies for cardiac diseases are not getting closer to clinical success. This review tries to unravel the obstacles and focuses on underlying mechanisms as the target for regenerative therapies. At present, the principal outcome in clinical therapy does not reflect experimental evidence. It seems that the scientific obstacle is a lack of integration of knowledge from tissue repair and disease mechanisms. Recent insights from clinical trials delineate mechanisms of stem cell dysfunction and gene defects in repair mechanisms as cause of atherosclerosis and heart disease. These findings require a redirection of current practice of stem cell therapy and a reset using more detailed analysis of stem cell function interfering with disease mechanisms. To accelerate scientific development the authors suggest intensifying unified computational data analysis and shared data knowledge by using open-access data platforms.
Biofilm production is not associated with poor clinical outcome in 485 patients with Staphylococcus aureus bacteraemia
Authors: M. Guembe, B. Alonso, J. Lucio, M.J. Pérez-Granda, R. Cruces, C. Sánchez-Carrillo, A. Fernández-Cruz, E. Bouza
Journal: Clinical Microbiology and Infection (2017)
Where Is the Road Map for Glioblastoma?
Authors: Jennifer A. Pinto-Martin
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
TCT-93 Stent based tissue drug and binding target protein distributions: durable versus deployable coatings
Authors: Abraham Tzafriri, Fernando Gacia-Polite, Xiaojian Li, John Keating, Josep Maria Balaguer, Brett Zani, Lynn Bailey, Peter Markham, Timothy Kiorpes, Elazer Edelman
Journal: Journal of the American College of Cardiology (2017)
Self-healing juvenile cutaneous mucinosis: Clinical and histopathologic findings of 9 patients
Authors: Isabelle Luchsinger, Jérôme Coulombe, Franco Rongioletti, Marc Haspeslagh, Anne Dompmartin, Isabelle Melki, Rawane Dagher, Brigitte Bader-Meunier, Sylvie Fraitag, Christine Bodemer
Journal: Journal of the American Academy of Dermatology (2017)
Reply to Nabi et al.
Authors: Qiu-Ning Wu, Xiao-Cen Zhang, Quan-Lin Li, Ping-Hong Zhou
Journal: Endoscopy (2017)

We thank Dr. Nabi and colleagues for their comments and were glad to see their opinions on submucosal fibrosis in achalasia patients and its impact on peroral endoscopic myotomy (POEM) [1]. Their comments open more discussion on this interesting topic.
Some Observations on Atrophic Gastritis and Gastric Cancer&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn2"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: Nathan Shapiro, Leon Schiff, Mary M. Maher, Max M. Zinninger
Journal: JNCI Journal of the National Cancer Institute (1942)

Journal Article Some Observations on Atrophic Gastritis and Gastric Cancer Get access Nathan Shapiro, Nathan Shapiro instructor in medicine University of Cincinnati Medical School Search for other works by this author on: Oxford Academic PubMed Google Scholar Leon Schiff, Leon Schiff associate professor of medicine University of Cincinnati Medical School Search for other works by this author on: Oxford Academic PubMed Google Scholar Mary M. Maher, Mary M. Maher fellow in gastroenterology Cincinnati General Hospital Search for other works by this author on: Oxford Academic PubMed Google Scholar Max M. Zinninger Max M. Zinninger associate professor of surgery University of Cincinnati Medical School Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 2, Issue 6, June 1942, Pages 583–588, https://doi.org/10.1093/jnci/2.6.583 Published: 01 June 1942
TCT-1 Direct Stenting Strategy is Associated with Improved Outcomes in Patients with Totally Occluded Culprit Arteries Undergoing Primary Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction
Authors: Ivan Bessonov, Igor Zyryanov, Stanislav Sapozhnikov, Vadim Kuznetsov
Journal: Journal of the American College of Cardiology (2017)
Induction Of Tumors In Guinea Pigs With Subcutaneously Injected Methylcholanthrene
Authors: Shimkin, Michael B., Mider, G. Burroughs
Journal: JNCI Journal of the National Cancer Institute (1941)

Journal Article Induction Of Tumors In Guinea Pigs With Subcutaneously Injected Methylcholanthrene Get access Michael B. Shimkin, Michael B. Shimkin assistant surgeon National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar G. Burroughs Mider G. Burroughs Mider research fellow National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 1, Issue 5, April 1941, Pages 707–725, https://doi.org/10.1093/jnci/1.5.707 Published: 01 April 1941
TCT-353 Effect of a New Enhanced Fluoroscopy Technology (Valve ASSIST2) on Contrast and Radiation Use in Patients Undergoing Transcatheter Aortic Valve Replacement
Authors: Ali Shafiq, Daniel P. O'Hair, Suhail Q. Allaqaband, Rafath Ullah, Tonga Nfor, Tanvir Bajwa
Journal: Journal of the American College of Cardiology (2017)
CCR5+ Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions
Authors: Carolin Blattner, Viktor Fleming, Rebekka Weber, Bianca Himmelhan, Peter Altevogt, Christoffer Gebhardt, Torsten J. Schulze, Hila Razon, Elias Hawila, Gizi Wildbaum, Jochen Utikal, Nathan Karin, Viktor Umansky
Journal: Cancer Research (2018)

Abstract Accumulation of myeloid-derived suppressor cells (MDSC) in melanoma microenvironment is supported by chemokine receptor/chemokine signaling. Although different chemokines were suggested to be involved in this process, the role of CCR5 and its ligands is not established. Using a Ret transgenic mouse melanoma model, we found an accumulation of CCR5+ MDSCs in melanoma lesions associated with both increased concentrations of CCR5 ligands and tumor progression. Tumor-infiltrating CCR5+ MDSCs displayed higher immunosuppressive activity than their CCR5− counterparts. Upregulation of CCR5 expression on CD11b+Gr1+ myeloid cells was induced in vitro by CCR5 ligands and other inflammatory factors. In melanoma patients, CCR5+ MDSCs were enriched at the tumor site and correlated with enhanced production of CCR5 ligands. Moreover, they exhibited a stronger immunosuppressive pattern compared with CCR5− MDSCs. Blocking CCR5/CCR5 ligand interactions increased survival of tumor-bearing mice and was associated with reduced migration and immunosuppressive potential of MDSCs in tumor lesions. Our findings define a critical role for CCR5 in recruitment and activation of MDSCs, suggesting a novel strategy for melanoma treatment. Significance: These findings validate the importance of the CCR5/CCR5 ligand axis not only for MDSC recruitment but also for further activation of their immunosuppressive functions in the tumor microenvironment, with potentially broad therapeutic implications, given existing clinically available inhibitors of this axis. Cancer Res; 78(1); 157–67. ©2017 AACR.
siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease
Authors: Emily P. Thi, Chad E. Mire, Amy C.H. Lee, Joan B. Geisbert, Raul Ursic-Bedoya, Krystle N. Agans, Marjorie Robbins, Daniel J. Deer, Robert W. Cross, Andrew S. Kondratowicz, Karla A. Fenton, Ian MacLachlan, Thomas W. Geisbert
Journal: Journal of Clinical Investigation (2017)

Ebolaviruses and marburgviruses belong to the family Filoviridae and cause high lethality in infected patients. There are currently no licensed filovirus vaccines or antiviral therapies. The development of broad-spectrum therapies against members of the Marburgvirus genus, including Marburg virus (MARV) and Ravn virus (RAVV), is difficult because of substantial sequence variability. RNAi therapeutics offer a potential solution, as identification of conserved target nucleotide sequences may confer activity across marburgvirus variants. Here, we assessed the therapeutic efficacy of lipid nanoparticle (LNP) delivery of a single nucleoprotein–targeting (NP-targeting) siRNA in nonhuman primates at advanced stages of MARV or RAVV disease to mimic cases in which patients begin treatment for fulminant disease. Sixteen rhesus monkeys were lethally infected with MARV or RAVV and treated with NP siRNA-LNP, with MARV-infected animals beginning treatment four or five days after infection and RAVV-infected animals starting treatment three or six days after infection. While all untreated animals succumbed to disease, NP siRNA-LNP treatment conferred 100% survival of RAVV-infected macaques, even when treatment began just 1 day prior to the death of the control animals. In MARV-infected animals, day-4 treatment initiation resulted in 100% survival, and day-5 treatment resulted in 50% survival. These results identify a single siRNA therapeutic that provides broad-spectrum protection against both MARV and RAVV.
Heat Shock Protein 70 Inhibitor, Alone or in Combination with Bortezomib, Prevented Plasmacytoma Development in Immunodeficient Mice Transplanted with Myeloma Cell Lines
Authors: Mariana Bleker de Oliveira, Angela Isabel Eugenio, Veruska Lia Fook Alves, Daniela Zanatta, Mihoko Yamamoto, Bryan Eric Strauss, Gisele W. B. Colleoni
Journal: Blood (2016)
TCT-252 Impact of diabetes on angina frequency and health status outcomes after bioresorbable scaffold implantation
Authors: Mariusz Tomaniak, Cordula Felix, Jiang Ming Fam, Evelyn Regar, Nicolas Van Mieghem, Joost Daemen, Jeroen Wilschut, Peter P.T. De Jaegere, Felix Zijlstra, Yoshinobu Onuma, Roberto Diletti, Robert-Jan van Geuns
Journal: Journal of the American College of Cardiology (2017)
Surgery for Drug-Resistant Epilepsy in Children
Authors: Rekha Dwivedi, Bhargavi Ramanujam, P. Sarat Chandra, Savita Sapra, Sheffali Gulati, Mani Kalaivani, Ajay Garg, Chandra S. Bal, Madhavi Tripathi, Sada N. Dwivedi, Rajesh Sagar, Chitra Sarkar, Manjari Tripathi
Journal: New England Journal of Medicine (2017)

Neurosurgical treatment may improve seizures in children and adolescents with drug-resistant epilepsy, but additional data are needed from randomized trials.In this single-center trial, we randomly assigned 116 patients who were 18 years of age or younger with drug-resistant epilepsy to undergo brain surgery appropriate to the underlying cause of epilepsy along with appropriate medical therapy (surgery group, 57 patients) or to receive medical therapy alone (medical-therapy group, 59 patients). The patients in the medical-therapy group were assigned to a waiting list for surgery. The primary outcome was freedom from seizures at 12 months. Secondary outcomes were the score on the Hague Seizure Severity scale, the Binet-Kamat intelligence quotient, the social quotient on the Vineland Social Maturity Scale, and scores on the Child Behavior Checklist and the Pediatric Quality of Life Inventory.At 12 months, freedom from seizures occurred in 44 patients (77%) in the surgery group and in 4 (7%) in the medical-therapy group (P<0.001). Between-group differences in the change from baseline to 12 months significantly favored surgery with respect to the score on the Hague Seizure Severity scale (difference, 19.4; 95% confidence interval [CI], 15.8 to 23.1; P<0.001), on the Child Behavior Checklist (difference, 13.1; 95% CI, 10.7 to 15.6; P<0.001), on the Pediatric Quality of Life Inventory (difference, 21.9; 95% CI, 16.4 to 27.6; P<0.001), and on the Vineland Social Maturity Scale (difference, 4.7; 95% CI, 0.4 to 9.1; P=0.03), but not on the Binet-Kamat intelligence quotient (difference, 2.5; 95% CI, -0.1 to 5.1; P=0.06). Serious adverse events occurred in 19 patients (33%) in the surgery group, including hemiparesis in 15 (26%).In this single-center trial, children and adolescents with drug-resistant epilepsy who had undergone epilepsy surgery had a significantly higher rate of freedom from seizures and better scores with respect to behavior and quality of life than did those who continued medical therapy alone at 12 months. Surgery resulted in anticipated neurologic deficits related to the region of brain resection. (Funded by the Indian Council of Medical Research and others; Clinical Trial Registry-India number, CTRI/2010/091/000525 .).